Dr. Mathew Garnett publishes a new review on genomics-guided precision medicine and drug development

The forward-looking review published in the journal Nature Cancer discusses key concepts in precision cancer medicine and how synthetic-lethal genetic screens can be leveraged to identify high-value oncology targets to develop better medicines for the treatment of molecularly-defined patients.


We are a cancer therapeutics company using advanced computational methods and next-generation cancer models to find new synthetic-lethal cancer targets. Our main mission is to tackle cancers with substantial unmet need by reinventing target discovery. We have active programmes across a variety of cancer indications and disease biology fields and we are seeking strategic alliances with pharma companies who wish to leverage our world-leading data and platforms.

Born out of pioneering research at the Wellcome Sanger Institute and anchored around a proprietary database that has seen 20 years of tuning and development, our tools and know-how will provide our partners with an unparalleled complement of world-leading capabilities.

For media and editorial enquiries, please email: contact@mosaic-tx.com